TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D3 and the Stress-axis in MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Relapsing Remitting MS~* At start of study \> 6 weeks in clinical remission of disease~* Age \> 18 years.~* Premenopausal~* Treated with either no immune-modulating treatment, or the currently registered MS modulating treatments: Interferon beta 1a (Rebif®), Interferon Beta 1b (Betaferon® or Avonex®), Glatiramer Acetate (Copaxone®), dimethylfumarate (Tecfidera®), teriflunomide (Aubagio®)) or fingolimod (Gilenya®).~Exclusion Criteria:~* Any contraindication to vitamin D according to Summary of Product Characteristics: Hypercalcaemia, hypervitaminosis D, nephrolithiasis, diseases or conditions resulting in hypercalcaemia and/or hypercalciuria (incl. primary hyperparathyroidism), severe renal impairment .~* Use of dexamethasone or other systemic glucocorticosteroids \<2 months prior to first study visit~* Supplementation of \>=1000 IU/d (25µg) vitamin D2 or D3~* Medical history of disturbed vitamin D/ calcium metabolism other than low intake~* Present clinical (major)depression~* Present treatment with anti-depressants, benzodiazepines, or neuroleptics.~* Treatment with high-dose dexamethasone for MS exacerbation during study.~* Pregnancy or the intention to become pregnant during the study period.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cholecalciferol (Type: EXPERIMENTAL): Patients receive 1dd 100ug vitamin D3 (drops) for 16 weeks
- Placebo comparator (Type: PLACEBO_COMPARATOR): placebo drops during 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Decline in Walking Performance in Adults With Cerebral Palsy - Influence of Performance Fatigability

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Common for CP and healthy volunteers:~* Capable of walking for six minutes without stopping~* Capable of consenting to the tests~Specific for the CP group~* GMFCS I or II at age 18~* Spastic diplegic cerebral palsy~Exclusion Criteria:~* Counter-indications to the test procedures~* Mental retardation or intelligence quotient (IQ) below 80~* Accompanying diseases not allowing for the test setup~* Major surgeries altering performance in the last six months~* Injection of botulin altering maximal force production in the last three months~* Refusing to sign the consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Patients with cerebral palsy (Type: EXPERIMENTAL): A specially adapted recumbent cycle ergometer with the ability to quickly transform into an isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
- Healthy people (Type: ACTIVE_COMPARATOR): A specially adapted recumbent cycle ergometer with the ability to quickly transform into an isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Predicting Lung Injury From Transfusion in Patients With Liver Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria: Subjects will be eligible to participate in the study if they meet all of the following criteria:~1. Admit to an ICU due to gastrointestinal bleeding AND an INR \> 1.5~2. Patient has chronic liver disease defined as 1 or more of the three following diagnostic criteria:~   1. Previous diagnosis of chronic liver disease OR Imaging or biopsy diagnosis of cirrhosis~  2. Signs of portal hypertension (ascites, varices, hypersplenism)~  3. Laboratory evidence of synthetic dysfunction (INR\>1.5, Bilirubin\> 2.0, Albumin\< 2.5) AND ≥2 physical exam findings on admission associated with chronic liver disease (palmar erythema, spider angiomata, asterixis, caput medusa, gynecomastia)~Exclusion criteria: Subjects will be ineligible to participate in the study if they meet any of the following criteria~1. Patient under age 18 OR pregnant OR incarcerated~2. Patient meets criteria for acute respiratory distress syndrome (ARDS) (PaO2/FiO2\<165)~3. Patient admitted to ICU for re-bleed on same hospital admission OR has already received \>4 units of plasma.~4. History of inheritable or acquired clotting or bleeding disorder~5. Patient actively anticoagulated or has recently received (within 72h) vitamin K antagonists, direct thrombin inhibitors, heparins or Xa antagonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Mechanism of Modified Utral-long Protocol in Improving Endometrial Receptivity in Patients With PCOS and IR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age\<36years,~* PCOS,~* Insulin resistance (HOMA-IR = fasting insulin (FINS) × fasting blood glucose (FPG) / 22.5, HOMA-IR ≥ 2.69 ）;~Exclusion Criteria:~* uterine abnormalities (double uterus, bicornuate uterus, unicornuate uterus and uterine mediastinum),~* intrauterine adhesions,~* endometriosis, adenomyosis,~* Hydrosalpinx,~* uterine fibroids (submucosal fibroids, non-mucosal fibroids \> 4 cm and / or endometrial pressure),~* Hyroid dysfunction and hyperprolactinemia.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): Modified Supper Long Protocol
- control group (Type: NO_INTERVENTION): long protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glucose Metabolism Disorders and Metabolic Syndrome Before and After Primary Hip and Knee Replacement

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Primary hip and knee replacement for osteoarthritis~* Enrolled previously into study NCT01021826~Exclusion Criteria:~* Arthritis other than osteoarthritis (based on study NCT01021826)~* Medication affecting glucose metabolism (excl. antidiabetic agents) (based on study NTC01021826)~* Died before follow-up phase~* Did not undergo the planned hip or knee replacement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Hip and knee replacement recipients (Type: None): Hip and knee replacement recipients (with osteoarthritis) enrolled previously into Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement study (NCT01021826).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation the Performance of Given Diagnostic System in Detection of Bleeding Events in the Small Bowel

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with overt GI bleeding (hematemesis, coffee-grounds, rectal bleeding and/or melena) with negative OGD but not critically ill, who should read positive on small bowel investigation (SBI)~2. Patients with occult GI bleeding (Faecal occult blood test,FOBT +)~3. Patients with suspected arteriovenous(AV) malformations.~4. Patients treated with nonsteroidal antiinflammatory drugs (NSAIDs)~5. Patients with active Crohn's disease(CD), with no evidence of obstruction~Exclusion Criteria:~1. In patients with known or suspected gastrointestinal obstruction, strictures, or fistulas based on the clinical picture or pre-ingestion testing and profile.~2. In patients with cardiac pacemakers or other implanted electromedical devices.~3. In patients with dysphagia or other swallowing disorders.~4. Unable to obtain informed written consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Colon 2 (Type: EXPERIMENTAL): using Colon 2 capsule in detecting bleeding events in small bowel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Early Elimination of Premature Ventricular Contractions in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with reduced ejection fraction (EF ≤45%) demonstrated by transthoracic echocardiogram and deemed to be non-ischemic by nuclear stress test or cardiac catheterization.~* Patients with \>20% PVCs on 24 hour holter-recording~* Patient is 18 years of age or older~* Optimized medical therapy on stable therapy for minimum 3 months with no changes in beta-blocker, ACE-I/ARB, digoxin doses (varying diuretic doses permitted).~Exclusion Criteria:~* Patients who are under the age of 18 years of age~* Patients with \>2 dominant PVC morphologies~* Patients with cardiac surgery in previous 3 months or scheduled for following 6 months~* Patients who were implanted with a biventricular device during the last three months or single/dual chamber device (with ventricular pacing \>10%) during the last three months~* Significant symptoms associated with PVCs that would make favor immediate ablation~* Intracardiac mural thrombus or myxoma~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ablation procedure vs medical therapy (Type: ACTIVE_COMPARATOR): PVC ablation vs medical therapy
- Compare 2 arms for safety, symptoms (Type: NO_INTERVENTION): Compare control of PVC's between 2 groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 and no older than 75 years of age~* Patient has moderate to severe, non-malignant chronic pain that is expected to last for at least 12 months and is currently taking an around-the-clock opioid to treat his/her pain~* Patient is already receiving opioid therapy, has demonstrated opioid tolerance, and requires a total daily dose of opioids at least equivalent to 25 mcg/hr of transdermal fentanyl. Patients who are considered opioid-tolerant are those who have been taking a daily dose of at least 30 mg of oral morphine or morphine equivalent opioid for at least 2 weeks.~Exclusion Criteria:~* Patient has active cancer~* Patient has a history of substance abuse or has a substance abuse disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Matrix Transdermal Fentanyl Patch (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with DKD~* Mean eGFR ≥ 15 and \< 60 mL/min/1.73 m²~* Albumin/creatinine ratio (ACR) ≤ 3500 mg/g Cr~* Treatment with an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin II receptor blocker (ARB) with no change in dosage or medication etc.~Exclusion Criteria:~* Diabetes mellitus that is neither type 1 nor type 2~* Decreased renal function mainly attributed to a non-diabetic cause~* History of renal transplantation or upcoming preemptive renal transplantation~* Confirmed mean systolic blood pressure \> 160 mmHg or a confirmed mean diastolic blood pressure \> 90 mmHg during the 8-week period before screening~* Hemoglobin A1c level \> 10.0% during screening~* Serum albumin level ≤ 3.0 g/dL during screening~* Cardiovascular disease specified in the study protocol~* History of cardiac failure~* BNP level \> 200 pg/mL during screening etc.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- RTA 402(Bardoxolone methyl) (Type: EXPERIMENTAL): Patients will receive multiple oral doses of bardoxolone methyl once daily. The starting dose of bardoxolone methyl will be 5 mg. The maximum dose will be 15 mg, and the dose will be increased by 5 mg.
- Placebo (Type: PLACEBO_COMPARATOR): Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Adherence to Medical Treatments for Telemedicine Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Phase 1 (Controls)~  * 18 - 75 years old~ * Good general health (self-reported), with no history of cerebral vascular accident (CVA)~ * English-speaking~ * Willingness and ability to comply with scheduled visits and study procedures~Phase 2 (Stroke Patients)~* 18 - 75 years old~* English-speaking~* Willingness and ability to comply with scheduled visits and study procedures~* Have requirements for home- based therapy regimens (i.e. physical/occupational therapy)~* Require medications for secondary stroke prevention (e.g. antithrombotic therapy to prevent ischemic stroke, stroke risk factor management with blood pressure, diabetes, cholesterol medications).~* Have a Modified Rankin Scale for Neurologic Disability (MDS) of 2 - 4~Exclusion Criteria:~* Phase 1 (Controls)~  * Pregnant women, fetuses, neonates, children, prisoners, cognitively impaired, non-English speaking subjects~ * Prohibitive cognitive impairments or language deficits~ * Does not have wireless internet connection at home~Phase 2 (Stroke Patients)~* Pregnant women, fetuses, neonates, children, prisoners, cognitively impaired, non-English speaking subjects~* Have a Modified Rankin Scale for Neurologic Disability (MDS) of 0-1 or 5~* Prohibitive cognitive impairments or language deficits~* Significant weakness, dystonia, or spasticity that will prevent proper use and response to the Apple Watch device~* Live in nursing home or rehabilitation facility~* Does not have wireless internet connection at home

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- MedRem application (Type: EXPERIMENTAL): MedRem smartwatch application

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study Evaluating Heart and Lung Metabolism in Pulmonary Hypertension Associated With Left Heart Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be able to provide their written informed consent to participate in the study after having received adequate previous information and prior to any study specific procedures.~* At least 18 years of age at the time of screening.~* Patients with PH secondary to left heart disease (known as group II PH) defined as a mean PAP\>25 mmHg and a PCWP of ≥15 mmHg.~Exclusion Criteria:~* All other types of pulmonary hypertension including Dana Point Classification Group 1, 3, 5.~* Type II Diabetes mellitus requiring medical therapy~* Previous myocardial infarction within the 3 months prior to screening.~* Renal insufficiency (glomerular filtration rate \< 30 ml/min.~* ALT or AST \> 3times ULN and/or severe hepatic insufficiency.~* Contraindication to MRI imaging.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FDG PET scan (Type: EXPERIMENTAL): A PET scan using F-18 FDG, N-13 Ammonia will be performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Prostatectomy patients with previously undetectable PSA and subsequent biochemical recurrence defined by PSA between 0.2 ng/ml and 1.0 ng/ml within 90 days prior to Fluciclovine scan~2. Age \>40~3. Ability to provide informed consent~Exclusion Criteria:~1. History of allergic reaction to Fluciclovine~2. Anti Androgen treatment in the 6 months prior to enrollment~3. Any patient whose body habitus, as determined by radiology personnel, will effectively inhibit the ability to obtain PET/CT imaging or will interfere with the images so as to make them clinically uninterpretable.

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group (Type: None): All patients receiving SOC imaging and Axumin PET scans.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Possible Brain Hormone Problems After Open Heart Surgery in Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children with congenital heart disease requiring cardiopulmonary bypass(CPB) surgery less than 1 year of age admitted to the cardiac intensive care unit (CICU) preoperatively, who required blood sampling as part of their care.~* Subject must have arterial or central venous lines to be enrolled.~* Subject must have a documented weight of 2.5 Kilograms or greater.~* Subjects' legal guardian shall possess the ability to understand the purposes and risks of the study and provide an informed consent signature.~Exclusion Criteria:~* Medical urgency preventing timely administration of the consenting process.~* Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating. Specific conditions might include, but are not limited to, anemia or coagulopathy.~* Have given steroids intravenously (IV) or oral steroids within the last month.~* Have a preexisting neuroendocrine disorder.~* Have been treated with antipsychotic medication.~* Have human immunodeficiency virus (HIV).~* Have received etomidate for intubation.~* Other technical considerations that would prevent acquisition of sufficient samples OR inability / unwillingness of the legal guardian to provide consent.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- Cardiac Surgery (Type: None): Infants with congenital defects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues